Wim J.G. Oyen
Radboud University Nijmegen
CancerRadiologySurgeryPathologyOncologyAntibodyChemistryImmunologyIn vivoPositron emission tomographyRadioimmunotherapyInflammationBiodistributionScintigraphyNuclear medicineCancer researchRadiation therapyColorectal cancerMonoclonal antibodyMedicine
Publications 840
#1Hedvig Hricak (Cornell University)H-Index: 109
#2May Abdel-Wahab (Hiroshima University)H-Index: 18
Last. Andrew M. ScottH-Index: 71
view all 17 authors...
The diagnosis and treatment of patients with cancer requires access to imaging to ensure accurate management decisions and optimal outcomes. Our global assessment of imaging and nuclear medicine resources identified substantial shortages in equipment and workforce, particularly in low-income and middle-income countries (LMICs). A microsimulation model of 11 cancers showed that the scale-up of imaging would avert 3·2% (2·46 million) of all 76·0 million deaths caused by the modelled cancers worldw...
7 CitationsSource
#1Seza A. GulecH-Index: 29
#2Sukhjeet Ahuja (Society of Nuclear Medicine and Molecular Imaging)H-Index: 4
Last. R. M. Tuttle (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 15
view all 17 authors...
BACKGROUND The American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association and the Society of Nuclear Medicine and Molecular Imaging have established an inter-societal working group to address the current controversies and evolving concepts in thyroid cancer management and therapy. The working group annually identifies topics that may significantly impact clinical practice and publishes expert opinion papers reflecting inter-societal collaboration...
#1Catharina M. Mulders-Manders (Radboud University Nijmegen)H-Index: 7
#2Ilse J.E. Kouijzer (Radboud University Nijmegen)H-Index: 9
Last. Chantal P. Bleeker-Rovers (Radboud University Nijmegen)H-Index: 36
view all 6 authors...
BACKGROUND: [18F]FDG-PET/CT is one of the most important diagnostic techniques in the work-up of patients with FUO/IUO. Little is known how to optimize the diagnostic value of [18F]FDG-PET/CT in patients with FUO/IUO. METHODS: Retrospective study in all patients who underwent [18F]FDG-PET/CT during the work-up of FUO/IUO in a tertiary expert center between 2005 and 2014. Data were extracted from medical records. RESULTS: 104 patients were identified, of whom 68 had a final diagnosis (65.4%), mai...
1 CitationsSource
#1Valentina Ambrosini (UNIBO: University of Bologna)H-Index: 38
#2Jolanta Kunikowska (Medical University of Warsaw)H-Index: 16
Last. James C. Yao (University of Texas MD Anderson Cancer Center)H-Index: 60
view all 31 authors...
Abstract Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a...
2 CitationsSource
#1Stefano Fanti (UNIBO: University of Bologna)H-Index: 67
#2Karolien Goffin (Katholieke Universiteit Leuven)H-Index: 25
Last. Anders BjartellH-Index: 58
view all 11 authors...
PURPOSE Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it....
10 CitationsSource
#1Gaël Chételat (French Institute of Health and Medical Research)H-Index: 63
#2Javier Arbizu (University of Navarra)H-Index: 29
Last. Alexander Drzezga (Forschungszentrum Jülich)H-Index: 32
view all 31 authors...
Various biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET, which assesses brain amyloid deposition, and 18F-fluorodeoxyglucose (18F-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information. However, uncertainty remains regarding the optimal timepoint, combination, and an order in which these PET biomarkers should be used in diagnostic evaluations...
20 CitationsSource
#1Tim J. van Oostenbrugge (Radboud University Nijmegen)H-Index: 6
#2Johan F. Langenhuijsen (Radboud University Nijmegen)H-Index: 17
Last. Peter F.A. Mulders (Radboud University Nijmegen)H-Index: 63
view all 8 authors...
Purpose Detection of residual or recurrent vital renal tumor on follow-up (FU) cross-sectional imaging after ablative therapy is challenging. The specific and high expression levels of carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma (ccRCC) makes it a suitable target for imaging using radiolabeled anti-CAIX antibody girentuximab. The objective of this study was to evaluate the feasibility of targeted FU imaging 1 month after cryoablation of ccRCC using single photon emission comp...
1 CitationsSource
#1Frederik A. Verburg (University of Marburg)H-Index: 9
#1Frederik A. VerburgH-Index: 34
Last. Douglas Van Nostrand (MedStar Washington Hospital Center)H-Index: 22
view all 19 authors...
2 CitationsSource
#1J. Alfred Witjes (Radboud University Nijmegen)H-Index: 78
#2Marek Babjuk (Charles University in Prague)H-Index: 24
Last. Alan Horwich (ICR: Institute of Cancer Research)H-Index: 81
view all 122 authors...
The authors regret that a co-author was mistakenly missed from the authorship. The following co-author should have been included in the authorship: Peter-Paul M. Willemse Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands
6 CitationsSource